Nathan M Shaw1, Shawn Marhamati1, Alexander Friedman2, Rachael Sussman1, Krishnan Venkatesan3,4. 1. Department of Urology, MedStar Georgetown, Washington, DC, USA. 2. Georgetown University School of Medicine, Washington, DC, USA. 3. Department of Urology, MedStar Georgetown, Washington, DC, USA. krishnan.venkatesan@medstar.net. 4. Department of Urology, MedStar Washington Hospital Center, 110 Irving St POB 3rd Floor, Washington, DC, 20010, USA. krishnan.venkatesan@medstar.net.
Abstract
PURPOSE: To evaluate the efficacy of deep bladder neck incision plus adjuvant Triamcinolone in the treatment of recurrent vesicourethral anastomotic stenosis following surgical treatment for prostate cancer. MATERIALS AND METHODS: A retrospective review of patients undergoing bladder neck incision from 2013 to 2019 was conducted. Patients who had previously undergone surgical treatment for prostate cancer and had failed treatment for bladder neck contracture were included. RESULTS: Twenty patients underwent deep bladder neck incision (BNI) with plasma button and adjuvant injection with a patency rate of 85%. Complete obliteration portended worst prognosis with 100% recurrence. CONCLUSIONS: Deep BNI with triamcinolone is a minimally morbid alternative for treatment of refractory vesicourethral anastomotic contractures.
PURPOSE: To evaluate the efficacy of deep bladder neck incision plus adjuvant Triamcinolone in the treatment of recurrent vesicourethral anastomotic stenosis following surgical treatment for prostate cancer. MATERIALS AND METHODS: A retrospective review of patients undergoing bladder neck incision from 2013 to 2019 was conducted. Patients who had previously undergone surgical treatment for prostate cancer and had failed treatment for bladder neck contracture were included. RESULTS: Twenty patients underwent deep bladder neck incision (BNI) with plasma button and adjuvant injection with a patency rate of 85%. Complete obliteration portended worst prognosis with 100% recurrence. CONCLUSIONS: Deep BNI with triamcinolone is a minimally morbid alternative for treatment of refractory vesicourethral anastomotic contractures.
Authors: Matthias D Hofer; Lee C Zhao; Allen F Morey; J Francis Scott; Andrew J Chang; Steven B Brandes; Chris M Gonzalez Journal: J Urol Date: 2013-12-12 Impact factor: 7.450
Authors: Timothy D Lyon; Nicholas J Farber; Leo C Chen; Thomas W Fuller; Benjamin J Davies; Jeffrey R Gingrich; Ronald L Hrebinko; Jodi K Maranchie; Jennifer M Taylor; Tatum V Tarin Journal: Adv Urol Date: 2015-12-21